Seres Therapeutics, Inc.
HealthcareNASDAQ:MCRB · NASDAQ Global Select
-$0.62 today
Vol 0.11M · Avg 0.05M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.1M of revenue converted into -$46.9M of net income for the selected period. Gross margin is -142.6% and net margin is -1681.5%, showing how much revenue survives after costs and taxes. EPS is $-5.17, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $789.0K | $0 | $0 | $0 -100.0% | $144.9M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $4.1M +17.0% | $3.5M | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$3.3M +5.3% | -$3.5M | $0 | $0 -100.0% | $144.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | -423.8% | — | — | — | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $49.1M -24.1% | $64.6M -45.1% | $117.6M +7.2% | $109.7M -22.7% | $141.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $39.2M -26.4% | $53.2M -31.4% | $77.5M +10.3% | $70.3M +1.4% | $69.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $90.6M -23.1% | $117.8M -39.6% | $195.1M +8.4% | $179.9M -14.1% | $209.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.1M -24.4% | $5.5M -12.4% | $6.2M -5.8% | $6.6M +11.5% | $5.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | $9.8M +108.2% | -$120.3M +33.7% | -$181.4M -6.1% | -$170.9M -201.4% | -$56.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 1245.8% | — | — | — | -39.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$94.0M +22.5% | -$121.3M +37.8% | -$195.1M -8.4% | -$179.9M -179.0% | -$64.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -11910.1% | — | — | — | -44.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.2M -43.9% | $4.0M -45.7% | $7.3M +138.8% | $3.1M +6.6% | $2.9M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 -100.0% | $13.2M +118.9% | $6.0M +106.9% | $2.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $99.7M +2336.7% | -$4.5M -189.7% | $5.0M +235.5% | -$3.7M -238.0% | -$1.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $5.7M +104.5% | -$125.8M +33.8% | -$190.1M -3.6% | -$183.6M -179.9% | -$65.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 721.9% | — | — | — | -45.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $5.7M +103.9% | -$146.6M -28.9% | -$113.7M +54.5% | -$250.2M -281.5% | -$65.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 721.9% | — | — | — | -45.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +103.4% | -$19 -6.1% | -$18 +61.6% | -$46 -223.7% | -$14 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +103.4% | -$19 -6.1% | -$18 +61.6% | -$46 -223.7% | -$14 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $8.9M +14.0% | $7.8M +21.4% | $6.4M +18.4% | $5.4M +17.9% | $4.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $8.9M +14.2% | $7.8M +21.4% | $6.4M +18.4% | $5.4M +17.9% | $4.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Seer, Inc.
NASDAQ:SEER
$94.57M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Actuate Therapeutics Inc
ACTU
$48.33M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
Applied Therapeutics, Inc.
APLT
$14.86M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MCRB generate?
Seres Therapeutics, Inc. (MCRB) reported $789,000.00 of revenue in fiscal 2025.
Is MCRB profitable?
Seres Therapeutics, Inc. (MCRB) reported $5.70M of net income, with a net margin of 721.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.